JLABS

There are 4 key differentiating factors your immunology innovation needs to make it stand out - click here to learn more about each one: jji.jnj/40DqsUY

Applying to become a JLABS resident or member? The first step is determining which incubation model suits your needs. Learn more here: jji.jnj/4kTbrYx

“This is an incredibly fast-moving area but there is still a lot of uncertainty and too little alignment between stakeholders on how to move forward.” Innovators weigh-in on advanced therapy medicinal products & cell and gene therapies in our blog here: jji.jnj/4rEF3KK

We're excited and proud to support companies that are looking to innovate in one of our strategic areas of focus. Learn more about the incubation application process today: jji.jnj/4kTbrYx

While innovations in ATMPs - such as cell and gene therapies - are generating excitement, few have translated into real-world patient benefit. To break barriers, Dutch stakeholders came together to form a national hub for advanced therapies. Learn more: jji.jnj/4rEF3KK

This year at the OBIO Investment Summit, we saw an incredible outlook for the momentum Canada has built in the biotech space. The event was attended by 112 life science companies and 109 investment funds. Here's what we learned onsite: jji.jnj/4rxykSR

It's easy to mistake activity for progress in early stage programs, and wading through datasets during partnering discussions can reveal large knowledge gaps. Make sure you're asking these 3 questions to avoid this pitfall: jji.jnj/40DDzWa

We recently sat down with JLABS San Francisco member company OmniScience to learn more about their mission, how they started, what the future holds, and what life looks like as a JLABS company. Read the full interview here: jji.jnj/4ldGL44

Wondering what the benefits of a JLABS residency are, or how a virtual membership works? Click here, learn more, and get ready to apply: jji.jnj/4rDaExq

Today we're shining a spotlight on OmniScience, a JLABS San Francisco member company working to unify clinical trial data into a system that will fundamentally transform how clinical development teams execute trials. Learn more here: jji.jnj/4ldGL44

This month's Innovation newsletter spans the globe – from a San Francisco-based company working to engineer novel antibodies, to a QuickFire Challenge awardee advancing precision ADC medicine. Sign up here: jji.jnj/4l2Z0cw

Interested in working with JLABS? Finding the right incubation option is the first step. We offer physical & virtual options to fit the needs of your startup. Explore here: jji.jnj/4rDaExq

Heading to BIO-Europe later this month? We’ll see you there!

Is your startup developing a new drug or asset? A collaboration with a pharma company may bring access to expertise, (non-dilutive) funding and networks which are otherwise hard to tap into. Join us in Utrecht or virtually on 19 March!

When building a collaboration with a startup, we always try to find a mix that is beneficial to both parties. This could include an investment by our Corporate VC. Hear from Citryll, a Dutch biotech tackling serious autoimmune diseases by resolving inflammation at its core.

Calling life science innovators: Herding Cats 3.0 returns this April to JLABS. Get real insights from Johnson & Johnson’s External Innovation Group, Lesley Stolz, and other Big Pharma leaders on navigating partnership opportunities. Apply by March 11. jji.jnj/4rpMg27

Final days to submit your novel AI technologies with potential to transform surgical care! Apply by February 27: jji.jnj/AIsurgeryQFC

“We designed Synthis around the idea that ADCs shouldn’t be limited to cytotoxic killing,” - Dori Thomas-Karyat, PhD, Founder & Chief Executive Officer of Synthis Therapeutics. Click here to learn more about the science behind Synthis Therapeutics: jji.jnj/4roM0jH

Deadline approaching! Apply to the Polyphonic™ AI Fund for Surgery QuickFire Challenge for a chance at $100k in award funding, mentorship, and more. Learn more: jji.jnj/AIsurgeryQFC

We're excited to spotlight JLABS member company Synthis Therapeutics! Synthis is pioneering a differentiated approach to ADCs, developing a new class of precision medicines that extend beyond traditional cytotoxic payloads. Read more here: jji.jnj/4roM0jH